An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs RG 7598 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 08 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2014 Planned End Date changed from 1 Nov 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 13 Aug 2013 Planned end date changed from 1 Jan 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top